NRG Meeting Banner for Website636777396428840063

Welcome to NRG Oncology!

Welcome to the NRG Oncology Web site! This resource serves to provide current information about NRG Oncology’s exciting research future and the latest updates about plans to support our clinical trial endeavors. We invite you to check back often to learn “what’s new.”

About NRG Oncology

NRG Oncology brings together the unique and complementary research areas of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). NRG Oncology builds upon our more than 150 years of cumulative research experience to conduct practice defining, multi-institutional clinical trials resulting in the improved survival and quality of life of patients with cancer. NRG Oncology has been awarded a grant by the National Cancer Institute (NCI) as a member of the NCI National Clinical Trials Network (NCTN).

Click here to access all weekly broadcasts

NCORP Badge English636404806468909532

NRG Oncology is proud to be an 
active participant of Cancer Moonshot.


Learn about the leaders and plans for NRG Oncology's NCORP Research Base.


NRG Oncology
Four Penn Center, 1600 JFK Blvd, Suite 1020, Philadelphia, PA 19103
Contact Us

To receive the NRG Oncology Newsletter and occasional eNews announcements and press releases, please email

What’s New

Applications for Health Disparities Committee Research Vice Chair – Deadline November 20, 2018. Click here for more information about the position and application submission.

Register today for the NRG-LU002 Webinar on November 29, 2018 Read more

NRG Oncology Newsletter Vol. 4 2018 is now available Read more

SBRT Considered Safe Treatment Option for Patients with Multiple (2-4) Metastases Read more

Combined therapy including pelvic lymph node radiation provides significant benefit for prostate cancer patients Read more

Radiation therapy outcomes better for African-American prostate cancer patients than Caucasian patients Read more

NRG-RTOG 9813 is the First Study to Identify the Impact of MGMT Gene Expression on Overall Survival for Patients with Anaplastic Glioma Tumors Read more

Short-Term Androgen-Deprivation Therapy with Radiotherapy Improves Survival over Radiotherapy Alone for up to 10 Years among Men with Early Stage Prostate Adenocarcinoma Read more

Patient Reported Outcomes on NRG-RTOG 0232 Indicate Brachytherapy Alone is the Superior Treatment for Men with Intermediate Risk Prostate Cancer Read more

Data Supports Interaction of Pretreatment Immune Inflammatory State of Patient Outcomes following Radiotherapy in High Risk Prostate Cancer Trial Read more

Applications for NRG Oncology Clinical Research Coordinator Mentor Program Now Open  Read More

The Addition of a CTLA4 Targeted Therapy to a PD-1 Targeted Therapy Could Benefit Women with Ovarian Cancer  Read more

Hurricane Florence Notice: Potential Impact on NRG Oncology Research Read more

Dr. Hudson Appointed to National Research Institute's Advisory Panel Read more

Cetuximab with radiation found to be inferior to standard treatment in HPV-positive oropharyngeal cancer. Read more

Catch up on all the news from the July 2018 NRG Oncology Semiannual Meeting. A special edition newsletter is now posted. Read more

The recording of the NRG Oncology Digital Health and Personal Connected Health Minisymposium is now posted. Read more 

NRG Oncology Newsletter Vol. 3 2018 now posted Read more

StereotacticBody Radiation Therapy (SBRT) May be an Effective and Safe Alternative for Patients with Medically Operable Early-Stage Lung Cancer Read more

MGMT Promoter Methylation Associated with Improved Survival for Patients with WHO Grade II Gliomas Read more

An Important Word from Quality Assurance staff about Protocol Amendments Read more

Dr. Chakravarti Selected to Serve on NCI Advisory Board of Scientific Counselors Read more

Dr. Felix Feng Selected as the New NRG Oncology Genitourinary Cancer Committee Chair Read more

Drs. Fisher & Wolmark receive SSO 2018 Charles M. Balch, MD Distinguished Service Award. Read more

NRG Oncology/RTOG 0126: Higher-Dose Radiotherapy Lowers Risk of Recurrence but Does Not Improve Survival for Men with Prostate Cancer Read more

Hurricane Florence Notice: Potential Impact on NRG Oncology Research
Hurricane Florence Notice: Potential Impact on NRG Oncology Research
Copyright 2018 by NRG Oncology